Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities.

Journal Article (Journal Article)

Tumors mutated in IDH1 tend to have lower levels of the essential substrate NAD+. In this issue of Cancer Discovery, Nagashima and colleagues exploit this metabolic sensitivity by devising a combinatorial therapy that both further reduces the pools as well as sequesters the remaining substrate in PAR chains, sensitizing the cells to temozolomide and PARG inhibition.See related article by Nagashima et al., p. 1672.

Full Text

Duke Authors

Cited Authors

  • Pirozzi, CJ; Yan, H

Published Date

  • November 2020

Published In

Volume / Issue

  • 10 / 11

Start / End Page

  • 1629 - 1631

PubMed ID

  • 33139340

Electronic International Standard Serial Number (EISSN)

  • 2159-8290

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-20-1215

Language

  • eng

Conference Location

  • United States